Foley & Lardner LLP partner Louis Lehot shared insights on the factors fueling the biotech IPO rebound in the Mergermarket article, “Biotech IPO window widens as M&A fuels 2026 revival.”
Lehot noted that large pharmaceutical companies facing patent expirations are increasingly turning to acquisitions to replenish their pipelines.
“Once a drug demonstrates commercial potential, larger drugmakers can provide the sales and marketing infrastructure needed to scale the product and may ultimately acquire the developer, either before or after an IPO,” he said.
Related News
September 17, 2026
In the News
Foley Featured in Law.com for Guiding Kontoor Brands in Sale of Lee®
Foley & Lardner LLP partner Bryan Schultz is featured for leading the Foley deal team which advised Kontoor Brands in the sale of its Lee® business in Law.com's “How the Deal Got Done” series.
September 15, 2026
In the News
David Rosen Shares Insights on FDA Efforts to Accelerate Human Clinical Trials
Foley & Lardner LLP partner David Rosen shared insights in the recent Law360 article, “FDA Seeks Applications For Project To Speed Up Human Trials,” on the FDA's pilot program pairing pharmaceutical companies with research institutions to accelerate human clinical trials.
September 15, 2026
In the News
Scott Ellis Addresses Cost Pressures Driven by Data Center Demand
Foley & Lardner LLP partner Scott Ellis was quoted in Politico’s recent article on the rising costs of building the energy infrastructure needed to support growing data center demand.